Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Sk Abdul AminTarun Jha

Abstract

For the last three decades, metalloenzymes such as histone deacetylases (HDACs) and matrix metalloproteinases (MMPs) have been identified in promoting solid as well as hematological carcinogenesis. Histone deacetylase 8 (HDAC-8), a class I HDAC enzyme, may serve as 'epigenetic player' that affects in the regulation of transcription factors and alters the structure of chromosome associated with tumorigenesis. It is established that the influence of MMP-2 in invasion, metastasis and angiogenenic events of hematological malignancies may be suppressed by HDAC inhibitors through reversion-inducing-cysteine-rich protein with kazal motifs (RECK) protein. Therefore, the isoform-specific HDAC-8 and MMP-2 inhibitors may provide synergistic medicinal benefit in leukemia. However, a paucity of articles is available on dual acting HDAC-8/MMP-2 inhibitors. In this circumstance, a lot of works are still necessary to identify novel dual HDAC-8/MMP-2 inhibitors and this review will surely provide an initial idea regarding the utility of designing such type of dual inhibitors. Here, the importance of MMP-2 and HDAC-8 inhibition in hematological malignancies are focussed for the first time as per our knowledge along with the structure-activity re...Continue Reading

Citations

Jun 29, 2018·Future Medicinal Chemistry·Sk Abdul AminTarun Jha
Jul 26, 2018·Journal of Biomolecular Structure & Dynamics·Sk Abdul AminBalaram Ghosh
Jan 12, 2019·Pharmaceutical Patent Analyst·Nilanjan AdhikariTarun Jha
Mar 27, 2019·Journal of Biomolecular Structure & Dynamics·Varun DewakerYenamandra S Prabhakar
May 11, 2019·Journal of Biomolecular Structure & Dynamics·Suvankar BanerjeeTarun Jha
Sep 19, 2019·Journal of Biomolecular Structure & Dynamics·Sk Abdul AminTarun Jha
Dec 31, 2018·European Journal of Medicinal Chemistry·Suvankar BanerjeeTarun Jha
Nov 5, 2020·European Journal of Medicinal Chemistry·Gargi Nikhil VaidyaDinesh Kumar
Sep 1, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yasser Hussein Eissa MohammedShaukath Ara Khanum
Sep 12, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sk Abdul AminTarun Jha
Jun 23, 2021·European Journal of Medicinal Chemistry·Sanjib DasTarun Jha
Aug 3, 2021·ACS Omega·Steven J TaylorNeil A Farrow
Apr 23, 2020·Journal of Medicinal Chemistry·Tingting LiuGuiyun Duan
Oct 13, 2021·Future Medicinal Chemistry·Saptarshi SanyalTarun Jha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.